From: Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
No. (%)
Clinical benefit
Median OS (months)
PR
1 (5.8)
7/17 (41%)
14
SD
6 (35.2)
PD
10 (58.8)
6.5
All 17 patients
10